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This is an official
CDC HEALTH UPDATE
Updated Interim U.S. Case Definition for Severe Acute Respiratory 
Syndrome (SARS)
The previous CDC SARS case definition (published April 30, 2003) has been updated as follows:
• Epidemiologic criteria for travel exposure have been updated to specify dates of illness onset for each area
• Interim criteria for exclusion of previously reported cases have been added
Clinical Criteria
• Asymptomatic or mild respiratory illness
• Moderate respiratory illness
—Temperature of >100.4° F (>38° C)*, and
—One or more clinical findings of respiratory illness (e.g., cough, shortness of breath, difficulty breathing, or 
hypoxia).
• Severe respiratory illness
—Temperature of >100.4° F (>38° C)*, and
—One or more clinical findings of respiratory illness (e.g., cough, shortness of breath, difficulty breathing, or 
hypoxia), and
— radiographic evidence of pneumonia, or
— respiratory distress syndrome, or
—autopsy findings consistent with pneumonia or respiratory distress syndrome without an identifiable cause.
Epidemiologic Criteria
• Travel (including transit in an airport) within 10 days of onset of symptoms to an area with current or previously 
documented or suspected community transmission of SARS (see Table), or
• Close contact§ within 10 days of onset of symptoms with a person known or suspected to have SARS
Travel criteria for suspect or probable U.S. cases of SARS
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Area First date o f illness onset for 
inclusion as reported case
Last date o f illness onset fo r 
inclusion as reported case
China (mainland) November 1, 2002 Ongoing
Hong Kong February 1, 2003 Ongoing
Hanoi, Vietnam February 1, 2003 May 25, 2003
Singapore February 1, 2003 Ongoing
Toronto, Canada April 23, 2003 May 30, 2003
Taiwan May 1, 2003 Ongoing
Laboratory Criteria
• Confirmed
— Detection of antibody to SARS-CoV in specimens obtained during acute illness or >21 days after illness onset, or
— Detection of SARS-CoV RNA by RT-PCR confirmed by a second PCR assay, by using a second aliquot of the 
specimen and a different set of PCR primers, or
— Isolation of SARS-CoV.
• Negative
—Absence of antibody to SARS-CoV in convalescent serum obtained >21 days after symptom onset.
• Undetermined
— Laboratory testing either not performed or incomplete.
Case Classification**
• Probable case: meets the clinical criteria for severe respiratory illness of unknown etiology and epidemiologic criteria 
for exposure; laboratory criteria confirmed, negative, or undetermined.
• Suspect case: meets the clinical criteria for moderate respiratory illness of unknown etiology, and epidemiologic 
criteria for exposure; laboratory criteria confirmed, negative, or undetermined.
Exclusion Criteria
A case may be excluded as a suspect or probable SARS case if:
• An alternative diagnosis can fully explain the illness***
• The case was reported on the basis of contact with an index case that was subsequently excluded as a case of SARS 
(e.g., another etiology fully explains the illness) provided other possible epidemiologic exposure criteria are not 
present
* A  measured documented temperature o f >100.4° F (>38° C) is preferred. However, clinical judgm ent should 
be used when evaluating patients fo r whom a measured temperature o f >100.4° F (>38° C) has not been 
documented. Factors that m ight be considered include patient self-report o f fever, use o f antipyretics, 
presence o f immunocomprom ising conditions or therapies, lack o f access to health care, or inability to obtain a 
measured temperature. Reporting authorities should consider these factors when classifying patients who do 
not strictly meet the clinical criteria fo r this case definition.
§  Close contact is defined as having cared fo r or lived with a person known to have SAR S or having a high 
likelihood o f direct contact with respiratory secretions and/or body fluids o f a patient known to have SARS. 
Examples o f close contact include kissing or embracing, sharing eating or drinking utensils, close 
conversation (<3 feet), physical examination, and any other direct physical contact between persons. Close 
contact does not include activities such as walking by a person or sitting across a waiting room or office for 
a brief period o f tim e.
J The W HO has specified that the surveillance period fo r China should begin on Novem ber 1; the first 
recognized cases in Hong Kong, Singapore and Hanoi (Vietnam) had onset in February 2003. The dates 
fo r Toronto and Taiwan are linked to CDC's issuance o f travel recommendations.
t  The last date fo r illness onset is 10 days (i.e., one incubation period) after removal o f a CDC travel alert.
The case patient's travel should have occurred on or before the last date the travel alert was in place.
Assays fo r the laboratory d iagnosis o f SARS-CoV infection include enzyme-linked immunosorbent assay, 
indirect fluorescent-antibody assay, and reverse transcription polymerase chain reaction (RT-PC R ) assays 
o f appropriately collected clinical specimens (Source: CDC. Guidelines fo r collection o f specimens from 
potential cases o f SARS. Available at h ttp://www.cdc.gov/ncidod/sars/specim en_collection_sars2.htm ). 
Absence o f SARS-CoV antibody from  serum obtained <21 days after illness onset, a negative PCR test, or 
a negative viral culture does not exclude coronavirus infection and is not considered a definitive laboratory 
result. In these instances, a convalescent serum specimen obtained >21 days after illness is needed to 
determ ine infection with SARS-CoV. All SARS diagnostic assays are under evaluation.
** Asym ptom atic SARS-CoV infection or clinical manifestations other than respiratory illness might be 
identified as more is learned about SARS-CoV infection.
*** Factors that may be considered in assigning alternate diagnoses include the strength of the 
epidem iologic exposure criteria fo r SARS, the specificity o f the diagnostic test, and the com patibility o f the 
clinical presentation and course o f illness fo r the alternative diagnosis.
The Centers fo r  Disease C ontro l and Prevention (CDC) p ro tec ts  people 's hea lth  and  sa fe ty  by p reven ting  and  
contro lling  diseases and  in ju rie s ; enhances hea lth  decisions by p rov id ing  credib le in fo rm a tion  on c ritica l health  
issues; and  prom otes hea lthy liv in g  through s trong  partne rsh ips w ith  loca l, na tiona l and  in te rna tiona l
organizations.
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